Adalimumab

Pharmacologic Category

Antirheumatic, Disease Modifying; Gastrointestinal Agent, Miscellaneous; Monoclonal Antibody; Tumor Necrosis Factor (TNF) Blocking Agent

Dosing: Adult

Note: Amjevita (adalimumab-atto) and Cyltezo (adalimumab-adbm) are approved as biosimilar agents to Humira. Approved uses may vary (consult product labeling).

Ankylosing spondylitis: SubQ: 40 mg every other week (may continue methotrexate, other nonbiologic DMARDS, corticosteroids, NSAIDs and/or analgesics).

Crohn disease: SubQ (may continue aminosalicylates and/or corticosteroids; if necessary, azathioprine or mercaptopurine may also be continued):

Initial: 160 mg (given on day 1 or split and given over 2 consecutive days), then 80 mg 2 weeks later (day 15).

Maintenance: 40 mg every other week beginning day 29. Note: Some patients may require 40 mg every week as maintenance therapy (Lichtenstein 2018).

Crohn disease management after surgical resection (off-label use): SubQ:

Initial: 160 mg (given on day 1), then 80 mg 2 weeks later (day 15) (Savarino 2013; Singh 2015). Note: Administer first infusion within 4 weeks after surgery in high-risk patients (Lichtenstein 2018).

Maintenance: 40 mg every 2 weeks (beginning day 29) (Savarino 2013; Singh 2015).

Crohn disease (perianal/fistulizing disease) (off-label use; Colombel 2009): SubQ:

Initial: 80 mg (given on day 1), then 40 mg 2 weeks later (day 15).

Maintenance: 40 mg every week or 40 mg every other week beginning day 29.

Hidradenitis suppurativa (Humira only): SubQ:

Initial: 160 mg (given on day 1 or split and given over 2 consecutive days), then 80 mg 2 weeks later (day 15).

Maintenance: 40 mg every week beginning day 29.

Plaque psoriasis: SubQ:

Initial: 80 mg as a single dose.

Maintenance: 40 mg every other week beginning 1 week after initial dose.

Psoriatic arthritis: SubQ: 40 mg every other week (may continue methotrexate, other nonbiologic DMARDS, corticosteroids, NSAIDs and/or analgesics).

Pyoderma gangrenosum (off-label use): SubQ: 40 to 80 mg every week or every other week (Fonder 2006; Heffernan 2007; Hubbard 2005; Jacob 2008). Additional data may be necessary to further define the role of adalimumab in the treatment of this condition.

Rheumatoid arthritis: SubQ: 40 mg every other week (may continue methotrexate, other nonbiologic DMARDS, corticosteroids, NSAIDs, and/or analgesics); patients not taking concomitant methotrexate may increase dose to 40 mg every week.

Ulcerative colitis: SubQ (may continue aminosalicylates and/or corticosteroids; if necessary, azathioprine, or mercaptopurine may also be continued):

Initial: 160 mg (given on day 1 or split and given over 2 consecutive days), then 80 mg 2 weeks later (day 15).

Maintenance: 40 mg every other week beginning day 29. Note: Only continue maintenance dose in patients demonstrating clinical remission by 8 weeks (day 57) of therapy.

Uveitis (Humira only): SubQ:

Initial: 80 mg as a single dose.

Maintenance: 40 mg every other week beginning 1 week after initial dose.

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Pediatric

Note: Amjevita (adalimumab-atto), Cyltezo (adalimumab-adbm), and Hyrimoz (adalimumab-adaz) are approved as biosimilar agents to Humira. Approved ages and uses may vary (consult product labeling).

Crohn disease; moderate to severe; refractory: Children ≥6 years and Adolescents:

17 kg to <40 kg: SubQ: Initial: 80 mg divided into 2 injections (40 mg each) on day 1, then 40 mg administered 2 weeks later (day 15); and then on day 29, begin maintenance dose: 20 mg every other week. Patients who continue to experience flares after 12 weeks of therapy may benefit from weekly dosing (Dubinsky 2016; Hyams 2012).

≥40 kg: SubQ: Initial: 160 mg divided into 4 injections (40 mg each, administered on one day or as 2 injections per day over 2 consecutive days), then 80 mg (divided into 2 injections [40 mg each] administered on one day) 2 weeks later (day 15); and then on day 29 begin maintenance dose: 40 mg every other week. Patients who continue to experience flares after 12 weeks of therapy may benefit from weekly dosing (Dubinsky 2016; Hyams 2012).

Hidradenitis suppurativa: Children ≥12 years and Adolescents: SubQ:

30 to <60 kg:

Initial: 80 mg on day 1, then 40 mg on day 8.

Maintenance: 40 mg every other week.

≥60 kg:

Initial: 160 mg (administered as full dose on day 1 or dose split and administered over 2 consecutive days), then 80 mg 2 weeks later (day 15).

Maintenance: 40 mg weekly beginning on day 29.

Juvenile idiopathic arthritis (JIA):

Fixed dosing:

Children 2 to 4 years:

10 kg to <15 kg: SubQ: 10 mg every other week.

15 to <30 kg: SubQ: 20 mg every other week.

Children ≥4 years and Adolescents:

15 kg to <30 kg: SubQ: 20 mg every other week.

≥30 kg: SubQ: 40 mg every other week.

Body surface area (BSA)-directed dosing: Note: Dosing based on trials performed with Humira product.

Children 2 to <4 years: SubQ: 24 mg/m2/dose every other week; maximum dose: 20 mg/dose (Humira Canadian product labeling 2018; Kingsbury 2014).

Children and Adolescents 4 to 17 years: SubQ: 24 mg/m2/dose every other week; maximum dose: 40 mg/dose (Burgos-Vargas 2015; Humira Canadian product labeling 2018; Lovell 2008).

Ulcerative colitis; moderate to severe, refractory: Limited data available: Children and Adolescents: SubQ: Initial: 100 mg/m2 (maximum dose: 160 mg/dose), then 50 mg/m2 (maximum dose: 80 mg/dose) 2 weeks later; then on day 29, begin maintenance therapy: 25 mg/m2 every other week (maximum dose: 40 mg/dose) (Turner 2012). Note: Trials performed with Humira product.

Uveitis (noninfectious intermediate, posterior, and panuveitis):

Fixed dosing: Children ≥2 years and Adolescents:

10 kg to <15 kg: SubQ: 10 mg every other week.

15 to <30 kg: SubQ: 20 mg every other week.

≥30 kg: SubQ: 40 mg every other week.

BSA-directed dosing: Children ≥4 years and Adolescents: SubQ: 24 or 40 mg/m2 every 2 weeks; maximum dose 40 mg/dose (Gallagher 2007; Simonini 2011). Dosing based on one prospective trial comparing 24 mg/m2/dose every 2 weeks of adalimumab (n=16, ages 6 to 12 years) to infliximab (n=17, ages 5 to 13 years) and on a retrospective trial of biologic response modifiers, including five patients who received adalimumab at 40 mg/m2/dose every 2 weeks. Note: Trials performed with Humira product.

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Use: Labeled Indications

Ankylosing spondylitis: Treatment (to reduce signs/symptoms) of active ankylosing spondylitis in adults.

Crohn disease: Treatment (to reduce signs/symptoms and to induce and maintain clinical remission) of active Crohn disease (moderate to severe) in adults and pediatric patients ≥6 years of age (Humira only) with an inadequate response to conventional therapy or who have lost response to or are intolerant to infliximab.

Hidradenitis suppurativa (Humira only): Treatment of moderate to severe hidradenitis suppurativa in adults and children ≥12 years of age.

Juvenile idiopathic arthritis: Treatment (to reduce signs/symptoms) of active polyarticular juvenile idiopathic arthritis (moderate to severe) in pediatric patients ≥2 years of age (Humira) or ≥4 years of age (Amjevita; Cyltezo); may be used alone or in combination with methotrexate.

Plaque psoriasis: Treatment of chronic plaque psoriasis (moderate to severe) in adults who are candidates for systemic therapy or phototherapy, and when other systemic therapies are less appropriate (with close monitoring and regular follow-up).

Psoriatic arthritis: Treatment (to reduce signs/symptoms, inhibit progression of structural damage, and improve physical function) of active psoriatic arthritis in adults; may be used alone or in combination with nonbiologic disease-modifying antirheumatic drugs (DMARDs).

Rheumatoid arthritis: Treatment (to reduce signs/symptoms, induce major clinical response, inhibit progression of structural damage, and improve physical function) of active rheumatoid arthritis (moderate to severe) in adults; may be used alone or in combination with methotrexate or other nonbiologic DMARDs.

Ulcerative colitis: Treatment (to induce and sustain clinical remission) of active ulcerative colitis (moderate to severe) in adults who have had an inadequate response to conventional therapy (Note: Efficacy in patients that are intolerant to or no longer responsive to other TNF blockers has not been established).

Uveitis (Humira only): Treatment of non-infectious intermediate, posterior, and panuveitis in adults and children ≥2 years of age.

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Crohn disease (management after surgical resection)Level of Evidence [B, G]

Data from a small prospective, randomized, controlled trial and a meta-analysis support the use of adalimumab in the management of Crohn disease after surgical resection and has demonstrated adalimumab lowers endoscopic and clinical recurrence rates Ref.

Based on the American Gastroenterological Association Institute Guideline on the Management of Crohn’s Disease after Surgical Resection and American College of Gastroenterology Guidelines on the Management of Crohn’s Disease in Adults, adalimumab is an effective first-line agent for prophylactic therapy in patients who are at higher risk for clinical recurrence following surgical resection.

Crohn disease (perianal/fistulizing disease)Level of Evidence [B, G]

Data from a randomized, placebo-controlled phase III trial support the use of adalimumab in the treatment and maintenance of long-term healing of draining fistulas in patients with Crohn disease Ref.

Based on the American College of Gastroenterology Guideline for the Management of Crohn’s Disease in Adults, adalimumab may be effective and should be considered in the management of perianal fistulas in patients with Crohn disease Ref.

Pyoderma gangrenosumLevel of Evidence [C]

Preliminary data suggest that adalimumab could be successful as an adjunct therapy or monotherapy for the treatment of severe pyoderma gangrenosum. Adalimumab has been shown to be beneficial in refractory pyoderma gangrenosum in cases in which infliximab and etanercept have failed. Controlled studies are needed to evaluate the efficacy and safety of adalimumab in order to fully determine its place in the treatment of pyoderma gangrenosum Ref.

Level of Evidence Definitions

Level of Evidence Scale

Class and Related Monographs

Tumor Necrosis Factor-Alpha Blockers (TNF-Alpha Blockers)

Comparative Efficacy

• ADALIMUMAB

Clinical Practice Guidelines

Ankylosing Spondylitis:

ACR/SAA/SPARTAN, "2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis," August 2019

Crohn Disease:

American College of Gastroenterology, “Management of Crohn's Disease in Adults,” March 2018

American College of Gastroenterology, “Management of Crohn’s Disease after Surgical Resection,” January 2017

American Gastroenterological Association, “Use of Thiopurines, Methotrexate, and Anti-TNF-alfa Biologic Drugs for Remission Induction and Maintenance in Inflammatory Crohn’s Disease,” 2013

Drug-Induced Liver Injury:

American College of Gastroenterology (ACG), “2014 ACG Guideline for Idiosyncratic Drug-induced Liver Injury,” July 2014

Inflammatory Bowel Disease:

American Gastroenterological Association Institute, “Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease,” September 2017

Juvenile Idiopathic Arthritis:

American College of Rheumatology, “2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis” 2013

Psoriatic Arthritis:

ACR/NPF, "Guideline for the Treatment of Psoriatic Arthritis," November 2018

Rheumatoid Arthritis:

American College of Rheumatology, "2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis,” 2015

Ulcerative Colitis:

American College of Gastroenterology, "Ulcerative Colitis in Adults," March 2019

Administration: Subcutaneous

For SubQ injection at separate sites in the thigh or lower abdomen (avoiding areas within 2 inches of navel); rotate injection sites. May leave at room temperature for ~15 to 30 minutes prior to use; do not remove cap or cover while allowing product to reach room temperature. Do not use if solution is discolored or contains particulate matter. Do not administer to skin which is red, tender, bruised, hard, or that has scars, stretch marks, or psoriasis plaques. Needle cap of the prefilled syringe or needle cover for the adalimumab pen may contain latex. Prefilled pens and syringes are available for use by patients and the full amount of the syringe should be injected (self-administration); the vial is intended for institutional use only. Vials do not contain a preservative; discard unused portion. Citrate-free formulations may be associated with less pain on injection.

Administration: Pediatric

SubQ: Administer subcutaneously into thigh or lower abdomen (avoid areas within 2 inches of navel); rotate injection sites. May leave at room temperature for ~15 to 30 minutes prior to use; do not remove cap or cover while allowing product to reach room temperature. Do not use if solution is discolored or contains particulate matter. Do not administer to skin which is red, tender, bruised, or hard. Needle cap of the prefilled syringe or needle cover for the adalimumab pen may contain latex. Prefilled pens and syringes are available for use by patients (self-administration); the Humira vial is intended for institutional use only and does not contain a preservative; discard unused portion. Citrate-free formulations may be associated with less pain on injection.

Storage/Stability

Store at 2°C to 8°C (36°F to 46°F) in original container to protect from light; do not freeze. Do not use if frozen even if it has been thawed. Do not store in extreme heat or cold. If needed, may be stored at room temperature up to a maximum of 25°C (77°F) for up to 14 days; discard if not used within 14 days.

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat some types of arthritis.

• It is used to treat Crohn's disease.

• It is used to treat ankylosing spondylitis.

• It is used to treat plaque psoriasis.

• It is used to treat ulcerative colitis.

• It is used to treat a skin problem called hidradenitis suppurativa.

• It is used to treat uveitis.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Common cold symptoms

• Abdominal pain

• Nausea

• Back pain

• Injection site irritation

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Infection

• Urinary tract infection like blood in the urine, burning or painful urination, passing a lot of urine, fever, lower abdominal pain, or pelvic pain

• Lupus like rash on the cheeks or other body parts, sunburn easy, muscle or joint pain, chest pain or shortness of breath, or swelling in the arms or legs

• Heart problems like cough or shortness of breath that is new or worse, swelling of the ankles or legs, abnormal heartbeat, weight gain of more than five pounds in 24 hours, dizziness, or passing out

• Aplastic anemia like fever, sore throat, mouth sores, infections, bruising, or purple skin splotches

• Liver problems like dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin

• Severe headache

• Burning or numbness feeling

• Severe dizziness

• Passing out

• Seizures

• Vision changes

• Extremity weakness

• Excessive weight loss

• Night sweats

• Persistent fever

• Swollen glands

• Skin growth

• Skin changes

• Mole changes

• Pale skin

• Skin eczema

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:

Abrilada (adalimumab-afzb): https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761118s000lbl.pdf#page=39

Amjevita (adalimumab-atto): https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761024s004lbl.pdf#page=39

Cyltezo (adalimumab-adbm): https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761058s003lbl.pdf#page=30

Hadlima (adalimumab-bwwd): https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761059s000lbl.pdf#page=36

Humira: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125057s403lbl.pdf#page=53

Hyrimoz (adalimumab-adaz): https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761071lbl.pdf#page=36

Contraindications

There are no contraindications listed in the manufacturer's US labeling.

Canadian labeling: Known hypersensitivity to adalimumab or any component of the formulation; severe infection (eg, sepsis, tuberculosis, opportunistic infection); moderate-to-severe heart failure (NYHA class III/IV)

Warnings/Precautions

Concerns related to adverse effects:

• Anaphylaxis/hypersensitivity reactions: May rarely cause hypersensitivity, anaphylaxis, anaphylactoid reactions, or angioneurotic edema; medications for the treatment of hypersensitivity reactions should be available for immediate use.

• Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome, have been reported; monitor and discontinue if symptoms develop.

• Demyelinating disease: Rare cases of new-onset or exacerbation of demyelinating disorders (eg, multiple sclerosis, optic neuritis, peripheral demyelinating disease, including Guillain-Barré syndrome) have been reported; there is a known association between intermediate uveitis and central demyelinating disorders. Consider discontinuing use in patients who develop peripheral or central nervous system demyelinating disorders during treatment. Use with caution in patients with preexisting or recent onset central or peripheral nervous system demyelinating disorders.

• Heart failure: Worsening and new-onset heart failure (HF) has been reported with adalimumab and other TNF blockers. Use with caution in patients with HF or decreased left ventricular function. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).

• Hematologic disorders: Rare cases of pancytopenia and aplastic anemia have been reported with TNF-blockers. Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with a history of significant hematologic abnormalities.

• Hepatitis B: Rare reactivation of hepatitis B (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants (some have been fatal); evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.

• Infections: [US Boxed Warning]: Patients receiving adalimumab are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate, corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (including reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral or other opportunistic infections (including legionellosis and listeriosis) have been reported. Monitor closely for signs/symptoms of infection during and after treatment. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to initiating therapy in patients with chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infections who develop severe systemic illness. Caution should be exercised when considering use in the elderly, patients with a history of an opportunistic infection, patients taking concomitant immunosuppressants (eg, corticosteroids, methotrexate), or in patients with conditions that predispose them to infections (eg, advanced or poorly controlled diabetes) or residence/travel in areas of endemic tuberculosis or mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent infections. Do not initiate adalimumab in patients with an active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.

• Malignancy: [US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescents receiving TNF-blocking agents, including adalimumab. Half of the malignancies reported in children and adolescents were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. Most patients were receiving concomitant immunosuppressants. [US Boxed Warning]: Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has been reported (some fatal) primarily in patients with Crohn disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly in adolescent and young adult males. The impact of adalimumab on the development and course of malignancy is not fully defined. Compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma and leukemia. A higher incidence of nonmelanoma skin cancers was noted in adalimumab-treated patients (0.7/100 patient years), when compared to the control group (0.2/100 patient years).

• Tuberculosis: [US Boxed Warnings]: Active tuberculosis (disseminated or extrapulmonary), including reactivation of latent tuberculosis, has been reported in patients receiving adalimumab. Evaluate patients for tuberculosis risk factors and latent tuberculosis infection (with a skin test) prior to and during therapy. Treatment for latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis during and after treatment. Consider antituberculosis treatment if an adequate course of treatment cannot be confirmed in patients with a history of latent or active tuberculosis or with risk factors despite negative skin test. Some patients who tested negative prior to therapy have developed active infection; tests for latent tuberculosis infection may be falsely negative while on adalimumab therapy. Use with caution in patients who have traveled to or resided in regions where tuberculosis is endemic. Monitor for signs and symptoms of tuberculosis in all patients.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Infection and malignancy has been reported at a higher incidence; use caution in elderly patients.

• Pediatric: Malignancies have been reported among children and adolescents.

• Surgery patients: Limited experience with patients undergoing surgical procedures while on therapy; consider long half-life with planned procedures. Monitor closely for infection.

Dosage form specific issues:

• Latex: The packaging (needle cover of prefilled syringe and autoinjector) may contain latex.

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Other warnings/precautions:

• Immunizations: Patients should be brought up to date with all immunizations before initiating therapy; live vaccines should not be given concurrently. There are no data available concerning the effects of therapy on vaccination or secondary transmission of live vaccines in patients receiving therapy.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

In studies, the elderly have an increased incidence of infection and malignancy compared to younger adults <65 years of age. Given the higher incidence of infections and malignancies in the elderly population, caution and close monitoring are recommended when using adalimumab in this population. Additionally, elderly patients with a history of HF may be at risk for HF exacerbation.

Warnings: Additional Pediatric Considerations

Postmarketing reports of lymphomas and other malignancies were primarily in pediatric patients with Crohn disease or ulcerative colitis treated with adalimumab and who received concomitant azathioprine or mercaptopurine; reports occurred predominantly in adolescent and young adult males. As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma. In an analysis of children and adolescents who had received TNF-blockers (etanercept and infliximab), the FDA identified 48 cases of malignancy. Of the 48 cases, ~50% were lymphomas (eg, Hodgkin and non-Hodgkin lymphoma). Other malignancies, such as leukemia, melanoma, and solid organ tumors were reported; malignancies rarely seen in children (eg, leiomyosarcoma, hepatic malignancies, and renal cell carcinoma) were also observed. Of note, most of these cases (88%) were receiving other immunosuppressive medications (eg, azathioprine and methotrexate). The role of TNF-blockers in the development of malignancies in children cannot be excluded. The FDA also reviewed 147 postmarketing reports of leukemia (including acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia) in patients (children and adults) using TNF-blockers. Average onset time to development of leukemia was within the first 1 to 2 years of TNF-blocker initiation.

Reactivation of TB has been reported in pediatric patients receiving biologic response modifiers (infliximab and etanercept); prior to therapy, patients with no TB risk factors should be screened for latent TB infection (LTBI) with an age appropriate test (ie, <5 years of age: tuberculin skin test, and ≥5 years of age: IGRA [interferon gamma release assay]); if any TB risk factors are present or symptoms, both LTBI screening tests should be performed (AAP [Davies 2016])

Reproductive Considerations

The American Academy of Dermatology considers tumor necrosis factor (TNF) blocking agents for the treatment of psoriasis to be compatible for use in male patients planning to father a child (AAD-NPF [Menter 2019]). Women with psoriasis planning a pregnancy may continue treatment with adalimumab. Women with well-controlled psoriasis who wish to avoid fetal exposure can consider discontinuing adalimumab 10 weeks prior to attempting pregnancy (Rademaker 2018).

Treatment algorithms are available for use of biologics in female patients with Crohn disease who are planning a pregnancy (Weizman 2019).

Pregnancy Considerations

Adalimumab crosses the placenta.

Adalimumab is a humanized monoclonal antibody (IgG1). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).

Following administration to pregnant patients with inflammatory bowel disease, cord blood and newborn serum concentrations of adalimumab are greater than maternal serum at delivery (Julsgaard 2016; Mahadevan 2013). The mean time to adalimumab clearance was 4 months (range: 2.9 to 5 months) in a study in 36 infants exposed in utero. The estimated mean half-life of adalimumab in these infants was 26 days (Julsgaard 2016). One case report notes adalimumab was detectable in the infant serum for 19 months following in utero exposure (Labetoulle 2018).

Outcome data from a pregnancy registry are available. Included were women with rheumatoid arthritis treated with adalimumab at least during the first trimester (n=74), women with RA not treated with adalimumab (n=80), and healthy pregnant women without RA (n=219). The incidence of major birth defects was not significantly different between the treatment groups. No pattern of specific defects was noted. There were no adverse pregnancy outcomes associated with therapy (Burmester 2017). Information related to this class of medications is emerging, but based on available data, tumor necrosis factor alpha (TNFα) blocking agents are considered to have low to moderate risk when used in pregnancy (ACOG 776 2019).

The risk of immunosuppression may be increased following third trimester maternal use of TNFα blocking agents; the fetus, neonate/infant should be considered immunosuppressed for 1 to 3 months following in utero exposure (AAD-NPF [Menter 2019]). Vaccination with live vaccines (eg, rotavirus vaccine) should be avoided for the first 6 months of life if exposure to a biologic agent occurs during the third trimester of pregnancy (eg, >27 weeks' gestation) (Mahadevan 2019).

Maternal adalimumab serum concentrations were found to remain stable during pregnancy in a study of nine women with Crohn disease (Seow 2017).

Inflammatory bowel disease is associated with adverse pregnancy outcomes including an increased risk of miscarriage, premature delivery, delivery of a low birth weight infant, and poor maternal weight gain. Management of maternal disease should be optimized prior to pregnancy. Treatment decreases disease flares, disease activity, and the incidence of adverse pregnancy outcomes (Mahadevan 2019).

Use of immune modulating therapies in pregnancy should be individualized to optimize maternal disease and pregnancy outcomes (ACOG 776 2019). The American Academy of Dermatology considers TNFα blocking agents for the treatment of psoriasis to be compatible with pregnancy (AAD-NPF [Menter 2019]). When treatment for inflammatory bowel disease is needed in pregnant women, appropriate biologic therapy can be continued without interruption. Serum levels should be evaluated prior to conception and optimized to avoid subtherapeutic concentrations or high levels which may increase placental transfer. Dosing can be adjusted so delivery occurs at the lowest serum concentration. For adalimumab, the final injection can be given 2 to 3 weeks prior to the estimated date of delivery (1 to 2 weeks if weekly dosing), then continued 48 hours postpartum (Mahadevan 2019).

Data collection to monitor pregnancy and infant outcomes following exposure to adalimumab is ongoing. Women exposed to adalimumab during pregnancy for the treatment of an autoimmune disease (eg, inflammatory bowel disease) may contact the OTIS Autoimmune Diseases Study at 877-311-8972.

Breast-Feeding Considerations

Adalimumab is present in breast milk

Based on information from three cases, adalimumab concentrations in breast milk are 0.1% to 1% of the maternal serum concentrations (Ben-Horin 2010; Fritzsche 2012). In one case, the highest milk concentration was observed 6 days following a maternal dose of adalimumab 40 mg SubQ when maternal treatment for Crohn disease was restarted 4 weeks' postpartum (Ben-Horin 2010). The same maternal dose was used in cases two and three. Adalimumab was not measurable (<40 ng/mL) in the serum of one breastfeeding infant (9 days after the last maternal dose, 8 weeks' postpartum); serum concentrations were not evaluated in the other infant (Fritzsche 2012). In a study of 21 women, only two had detectable adalimumab in their breast milk, with maximum concentrations occurring between 12 and 24 hours after the infusion (dose not stated) (Matro 2018). An increased risk of infection has not been observed in breastfeeding infants whose mothers were using adalimumab monotherapy (Mahadevan 2012).

According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. However, tumor necrosis factor alpha (TNFα) blocking agents are considered compatible with breastfeeding (AAD-NPF [Menter 2019]; ACOG 776 2019; Mahadevan 2019).

Briggs' Drugs in Pregnancy & Lactation

• Adalimumab

Adverse Reactions

>10%:

Central nervous system: Headache (12%)

Dermatologic: Skin rash (6% to 12%)

Hematologic & oncologic: Positive ANA titer (12%)

Immunologic: Antibody development (3% to 26%)

Infection: Infection (children and adolescents: 45%)

Local: Injection site reaction (5% to 20%)

Neuromuscular & skeletal: Increased creatine phosphokinase (15%)

Respiratory: Upper respiratory tract infection (17%), sinusitis (11%)

1% to 10%:

Cardiovascular: Hypertension (5%), atrial fibrillation (<5%), cardiac arrhythmia (<5%), chest pain (<5%), coronary artery disease (<5%), deep vein thrombosis (<5%), hypertensive encephalopathy (<5%), myocardial infarction (<5%), palpitations (<5%), pericardial effusion (<5%), pericarditis (<5%), peripheral edema (<5%), subdural hematoma (<5%), syncope (<5%), tachycardia (<5%)

Central nervous system: Confusion (<5%), myasthenia (<5%), paresthesia (<5%), torso pain (<5%)

Dermatologic: Cellulitis, erysipelas

Endocrine & metabolic: Hyperlipidemia (7%), hypercholesterolemia (6%), dehydration (<5%), ketosis (<5%), menstrual disease (<5%), parathyroid disease (<5%)

Gastrointestinal: Nausea (9%), abdominal pain (7%), cholecystitis (<5%), cholelithiasis (<5%), esophagitis (<5%), gastrointestinal hemorrhage (<5%), vomiting (<5%), diverticulitis of the gastrointestinal tract

Genitourinary: Urinary tract infection (≤8%), hematuria (5%), cystitis (<5%), pelvic pain (<5%)

Hematologic & oncologic: Adenoma (<5%), agranulocytosis (<5%), paraproteinemia (<5%), polycythemia (<5%), carcinoma (including breast, gastrointestinal, skin, urogenital), malignant lymphoma, malignant melanoma

Hepatic: Increased serum alkaline phosphatase (5%), hepatic necrosis (<5%)

Hypersensitivity: Hypersensitivity reaction (children 5% to 6%; adults 1%)

Infection: Serious infection (4%), herpes simplex infection (≤4%), herpes zoster infection (≤4%), sepsis

Neuromuscular & skeletal: Back pain (6%), arthritis (<5%), arthropathy (<5%), bone disease (<5%), bone fracture (<5%), limb pain (<5%), muscle cramps (<5%), myasthenia (<5%), osteonecrosis (<5%), septic arthritis (<5%), synovitis (<5%), tendon disease (<5%), tremor (<5%), arthralgia (3%; plaque psoriasis)

Ophthalmic: Cataract (<5%)

Renal: Nephrolithiasis (<5%), pyelonephritis

Respiratory: Flu-like symptoms (7%), asthma (<5%), bronchospasm (<5%), dyspnea (<5%), pleural effusion (<5%), respiratory depression (<5%), pharyngitis (juvenile idiopathic arthritis: ≤4%), pneumonia (≤4%), tuberculosis (including reactivation of latent infection; disseminated, miliary, lymphatic, peritoneal, and pulmonary)

Miscellaneous: Accidental injury (10%), abnormal healing (<5%), postoperative complication (infection)

<1%, postmarketing, and/or case reports: Abscess (limb, perianal), alopecia, anal fissure, anaphylactoid shock, anaphylaxis, anemia, angioedema, aplastic anemia, appendicitis, asthenia, bacterial infection, basal cell carcinoma, blepharitis, bronchitis, cardiac failure, cerebrovascular accident, cervical dysplasia, circulatory shock, clonus, cytopenia, dermal ulcer, diarrhea, diplopia, endometrial hyperplasia, eosinophilia, erythema multiforme, fever, fixed drug eruption, fulminant necrotizing fasciitis, fungal infection, Guillain-Barré syndrome, hepatic failure, hepatitis B (reactivation), hepatosplenic T-cell lymphomas (children, adolescents, and young adults), hepatotoxicity (idiosyncratic) (Chalasani 2014), histoplasmosis, hyperreflexia, hypersensitivity angiitis, increased serum transaminases, interstitial pulmonary disease (including pulmonary fibrosis), intestinal obstruction, intestinal perforation, leukemia, leukopenia, lichenoid eruption, liver metastases, lupus-like syndrome, lymphadenopathy, lymphocytosis, malignant neoplasm of ovary, meningitis (viral), Merkel cell carcinoma, multiple sclerosis, musculoskeletal chest pain, mycobacterium avium complex, myositis (children and adolescents), neutropenia, nocturia, optic neuritis, pancreatitis, pancytopenia, protozoal infection, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pulmonary embolism, respiratory failure, sarcoidosis, septic shock, skin granuloma (annulare; children and adolescents), Stevens-Johnson syndrome, streptococcal pharyngitis (children and adolescents), supraventricular cardiac arrhythmia, swelling of eye, systemic lupus erythematosus, testicular neoplasm, thrombocytopenia, urticaria, vascular disease, vasculitis (systemic), viral infection

* See Cautions in AHFS Essentials for additional information.

Allergy and Idiosyncratic Reactions

• Adalimumab Allergy
• Monoclonal Antibody Allergy

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. Risk X: Avoid combination

Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. Risk X: Avoid combination

BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

Belimumab: May enhance the immunosuppressive effect of Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Risk X: Avoid combination

Biologic Disease-Modifying Antirheumatic Drugs (DMARDs): May enhance the immunosuppressive effect of other Biologic Disease-Modifying Antirheumatic Drugs (DMARDs). Risk X: Avoid combination

Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. Risk X: Avoid combination

Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. Risk X: Avoid combination

Cladribine: May enhance the immunosuppressive effect of Immunosuppressants. Risk X: Avoid combination

Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Risk C: Monitor therapy

CycloSPORINE (Systemic): Adalimumab may decrease the serum concentration of CycloSPORINE (Systemic). Risk C: Monitor therapy

Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Risk C: Monitor therapy

Echinacea: May diminish the therapeutic effect of Immunosuppressants. Management: Consider avoiding Echinacea in patients receiving therapeutic immunosuppressants. If coadministered, monitor for reduced efficacy of the immunosuppressant during concomitant use. Risk D: Consider therapy modification

Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Risk D: Consider therapy modification

Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Risk D: Consider therapy modification

Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Risk X: Avoid combination

Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Management: Avoid use of immunosuppressants (including systemic corticosteroids) prior to initiation of nivolumab. Use of immunosuppressants after administration of nivolumab (eg, for immune-related toxicity) is unlikely to affect nivolumab efficacy. Risk D: Consider therapy modification

Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Risk C: Monitor therapy

Ozanimod: Immunosuppressants may enhance the immunosuppressive effect of Ozanimod. Risk C: Monitor therapy

Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. Risk C: Monitor therapy

Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Risk X: Avoid combination

Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. Risk X: Avoid combination

Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Management: Consider avoiding concomitant use of roflumilast and immunosuppressants as recommended by the Canadian product monograph. Inhaled or short-term corticosteroids are unlikely to be problematic. Risk D: Consider therapy modification

Siponimod: Immunosuppressants may enhance the immunosuppressive effect of Siponimod. Risk C: Monitor therapy

Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Management: Evaluate patients to see if it is medically appropriate to reduce or discontinue therapy with immunosuppressants prior to initiating sipuleucel-T therapy. Risk D: Consider therapy modification

Smallpox and Monkeypox Vaccine (Live): Immunosuppressants may diminish the therapeutic effect of Smallpox and Monkeypox Vaccine (Live). Risk C: Monitor therapy

Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Risk X: Avoid combination

Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. Risk C: Monitor therapy

Theophylline Derivatives: Adalimumab may decrease the serum concentration of Theophylline Derivatives. Exceptions: Dyphylline. Risk C: Monitor therapy

Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. Risk C: Monitor therapy

Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents. Risk X: Avoid combination

Trastuzumab: May enhance the neutropenic effect of Immunosuppressants. Risk C: Monitor therapy

Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Risk D: Consider therapy modification

Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants. Exceptions: Smallpox and Monkeypox Vaccine (Live). Risk X: Avoid combination

Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. Risk X: Avoid combination

Warfarin: Adalimumab may decrease the serum concentration of Warfarin. Risk C: Monitor therapy

Monitoring Parameters

Monitor improvement of symptoms and physical function assessments. Latent TB screening prior to initiating and during therapy; signs/symptoms of active infection, including tuberculosis (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss), including periodic skin examination. The American Gastroenterological Association suggests reactive therapeutic drug monitoring to guide treatment changes in adult patients treated with adalimumab for active inflammatory bowel disease (Feuerstein 2017).

Reference Range

Inflammatory bowel disease (IBD):

Reactive therapeutic drug monitoring has been suggested to guide treatment changes in adults with active IBD.

Timing of serum sample: Draw trough <24 hours prior to next scheduled dose

Therapeutic reference range: ≥7.5 mcg/mL (Feuerstein 2017)

Advanced Practitioners Physical Assessment/Monitoring

Obtain CBC with differential and liver function tests. Ensure patients are up to date on immunizations prior to starting therapy. Do not give live vaccines during treatment. Perform tuberculin skin test prior to initiating therapy. Assess results of PPD at regular intervals during treatment, false negatives may occur. Monitor for signs of tuberculosis throughout therapy. Do not initiate therapy if active infection is present. Obtain HBV screening prior to initiating. Monitor for signs and symptoms of infection, enlarged lymph nodes, or skin lesions/eruptions. Assess other medications patient may be taking; alternative therapy or dosage adjustments may be needed. Obtain periodic dermatologic exams. Monitor for signs or symptoms of hypersensitivity reactions, lupus-like syndrome, malignancy, or worsening or new onset heart failure.

Nursing Physical Assessment/Monitoring

Check ordered labs and report any abnormalities. Monitor for signs and symptoms of tuberculosis, other infections, enlarged lymph nodes, or skin lesions/eruptions. Assess for liver dysfunction (unusual fatigue, easy bruising or bleeding, jaundice). Monitor PPD at regular intervals during treatment, false negatives may occur. Educate patient on proper injection technique, site rotation, and syringe/needle disposal. Educate latex-sensitive patients that needle cap of prefilled syringe may contain latex. Monitor for signs and symptoms of hypersensitivity reactions, lupus-like syndrome, or malignancy.

Product Availability

Abrilada (adalimumab-afzb): FDA approved November 2019; availability anticipated in 2023. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.

Amjevita (adalimumab-atto): FDA approved September 2016; anticipated availability is currently unknown. Amjevita is approved as biosimilar to Humira. Consult the prescribing information for additional information.

Cyltezo (adalimumab-adbm): FDA approved August 2017; anticipated availability is currently unknown. Cyltezo is approved as biosimilar to Humira. Information pertaining to this product within the monograph is pending revision. Consult the prescribing information for additional information.

Hadlima (adalimumab-bwwd): FDA approved July 2019; anticipated availability is currently unknown. Hadlima is approved as biosimilar to Humira. Consult the prescribing information for additional information.

Dosage Forms Considerations

The 10 mg/0.1 mL, 20 mg/0.2 mL, 40 mg/0.4 mL, and 80 mg/0.8 mL formulations are citrate free.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Pen-injector Kit, Subcutaneous [preservative free]:

Humira Pen: 40 mg/0.8 mL (1 ea); 40 mg/0.4 mL (1 ea) [contains polysorbate 80]

Humira Pen-CD/UC/HS Starter: 40 mg/0.8 mL (1 ea); 80 mg/0.8 mL (1 ea) [contains polysorbate 80]

Humira Pen-Ps/UV/Adol HS Start: 40 mg/0.8 mL (1 ea); 80 MG/0.8ML & 40MG/0.4ML (1 ea) [contains polysorbate 80]

Prefilled Syringe Kit, Subcutaneous [preservative free]:

Humira: 10 mg/0.2 mL (1 ea); 20 mg/0.4 mL (1 ea); 40 mg/0.8 mL (1 ea); 10 mg/0.1 mL (1 ea); 20 mg/0.2 mL (1 ea); 40 mg/0.4 mL (1 ea) [contains polysorbate 80]

Humira Pediatric Crohns Start: 40 mg/0.8 mL (1 ea); 80 mg/0.8 mL (1 ea); 80 MG/0.8ML & 40MG/0.4ML (1 ea) [contains polysorbate 80]

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Subcutaneous:

Humira: 40 mg/0.8 mL (1 mL) [contains polysorbate 80]

Solution Pen-injector, Subcutaneous:

Humira: 40 mg/0.4 mL (0.4 mL) [contains polysorbate 80]

Solution Prefilled Syringe, Subcutaneous:

Humira: 40 mg/0.4 mL (0.4 mL) [contains polysorbate 80]

Anatomic Therapeutic Chemical (ATC) Classification

• L04AB04

Generic Available (US)

No

Pricing: US

Pen-injector Kit (Humira Pen Subcutaneous)

40 mg/0.4 mL (per each): $3,334.18

40 mg/0.8 mL (per each): $3,334.18

Pen-injector Kit (Humira Pen-CD/UC/HS Starter Subcutaneous)

40 mg/0.8 mL (per each): $3,334.19

80 mg/0.8 mL (per each): $6,668.39

Pen-injector Kit (Humira Pen-Ps/UV/Adol HS Start Subcutaneous)

40 mg/0.8 mL (per each): $3,334.19

80 MG/0.8ML &40MG/0.4ML (per each): $4,445.58

Prefilled Syringe Kit (Humira Pediatric Crohns Start Subcutaneous)

80 mg/0.8 mL (per each): $6,668.39

80 MG/0.8ML &40MG/0.4ML (per each): $5,001.29

Prefilled Syringe Kit (Humira Subcutaneous)

10 mg/0.2 mL (per each): $3,334.18

10MG/0.1ML (per each): $3,334.18

20 mg/0.2 mL (per each): $3,334.18

20 mg/0.4 mL (per each): $3,334.18

40 mg/0.4 mL (per each): $3,334.18

40 mg/0.8 mL (per each): $3,334.18

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Adalimumab is a recombinant monoclonal antibody that binds to human tumor necrosis factor alpha (TNF-alpha), thereby interfering with binding to TNFα receptor sites and subsequent cytokine-driven inflammatory processes. Elevated TNF levels in the synovial fluid are involved in the pathologic pain and joint destruction in immune-mediated arthritis. Adalimumab decreases signs and symptoms of psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. It inhibits progression of structural damage of rheumatoid and psoriatic arthritis. Reduces signs and symptoms and maintains clinical remission in Crohn disease and ulcerative colitis; reduces epidermal thickness and inflammatory cell infiltration in plaque psoriasis.

Pharmacodynamics/Kinetics

Distribution: Vd: 4.7 to 6 L; Synovial fluid concentrations: 31% to 96% of serum

Bioavailability: Absolute: 64%

Half-life elimination: Terminal: ~2 weeks (range: 10 to 20 days)

Time to peak, serum: SubQ: 131 ± 56 hours

Pharmacodynamics/Kinetics: Additional Considerations

Geriatric: In patients with rheumatoid arthritis (RA), there was a trend toward lower clearance with increasing age in patients 40 to >75 years of age.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Adalimumab belongs to the class of disease-modifying antirheumatic drugs and, as such, has immunosuppressive properties. Consider a medical consult prior to any invasive treatment for patients under active treatment with adalimumab. Delayed wound healing due to the immunosuppressive effects and increased potential for postsurgical infection may be of concern.

Effects on Bleeding

Rare reports of pancytopenia (including aplastic anemia), as well as medically significant thrombocytopenia, have been reported with tumor necrosis factor-alpha therapy; in patients undergoing active treatment, a medical consult is recommended

Index Terms

Abrilada; Adalimumab-adbm; Adalimumab-afzb; Adalimumab-atto; Amjevita; Antitumor Necrosis Factor Alpha (Human); Cyltezo; D2E7; Human Antitumor Necrosis Factor Alpha

FDA Approval Date

December 31, 2002

References

Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.[PubMed 3960626]

American College of Obstetricians and Gynecologists (ACOG). Committee opinion no. 776: immune modulating therapies in pregnancy and lactation. Obstet Gynecol. 2019;133(4):e287-e295.[PubMed 30913201]

Amjevita (adalimumab-atto) [prescribing information]. Thousand Oaks, CA: Amgen Inc; June 2019.

Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol. 2010;8(5):475-476.[PubMed 20005982]

Burgos-Vargas R, Tse SM, Horneff G, et al. A randomized, double-blind, placebo-controlled multicenter study of adalimumab in pediatric patients with enthesitis-related arthritis. Arthritis Care Res (Hoboken). 2015;67(11):1503-1512.[PubMed 26223543]

Burmester GR, Landewé R, Genovese MC, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(2):414-417.[PubMed 27338778]

Burmester GR, Panaccione R, Gordon KB, et al, "Adalimumab: Long-Term Safety in 23 458 Patients From Global Clinical Trials in Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis and Crohn's Disease," Ann Rheum Dis, 2012.[PubMed 22562972]

Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199. http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm[PubMed 6423951]

Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html. Updated January 5, 2012. Accessed January 9, 2012.

Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950-966.[PubMed 24935270]

Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009;58(7):940-948. doi: 10.1136/gut.2008.159251.[PubMed 19201775]

Cyltezo (adalimumab-adbm) [prescribing information]. Ridgefield, CT; Boehringer Ingelheim Pharmaceuticals, Inc: September 2019.

Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145(6):1464-1478.[PubMed 24267475 ]

Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. Pediatrics. 2016;138(2):e20161209.[PubMed 27432853]

Dommasch E and Gelfand JM, “Is There Truly a Risk of Lymphoma From Biologic Therapies?” Dermatol Ther, 2009, 22 (5):418-30.

Dubinsky MC, Rosh J, Faubion WA Jr, et al. Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease. Inflamm Bowel Dis. 2016;22(4):886-893.[PubMed 26950307]

Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032.[PubMed 28780013]

Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford). 2016;55(9):1693-1697.[PubMed 26750124]

Fonder MA, Cummins DL, Ehst BD, et al. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006;5:e8.[PubMed 17149453]

Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012;46(8):718-719.[PubMed 22858514]

Gallagher M, Quinones K, Cervantes-Castañeda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91(10):1341-1344.[PubMed 17556427 ]

Gordon KB, Langley RG, Leonardi C, et al, “Clinical Response to Adalimumab Treatment in Patients With Moderate to Severe Psoriasis: Double-Blind, Randomized Controlled Trial and Open-Label Extension Study,” J Am Acad Dermatol, 2006, 55(4):598-606.[PubMed 17010738]

Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810.[PubMed 26888948]

Hadlima (adalimumab-bwwd) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; July 2019.

Heffernan MP, Anadkat MJ, Smith DL. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007;143(3):306-308.[PubMed 17372094]

Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152(5):1059-1061.[PubMed 15888172]

Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc; March 2020.

Humira (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2019.

Humira (adalimumab) [product monograph]. St-Laurent, Quebec, Canada: AbbVie Corporation; June 2019.

Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology. 2012;143(2):365-374.[PubMed 22562021]

Hyrimoz (adalimumab) [prescribing information]. Princeton, NJ: Sandoz Inc; October 2018.

Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47(5):312-313.[PubMed 12534540]

Jacob SE, Wiesman RS, Kerdel FA. Pyoderma gangrenosum—rebel without a cure? Int J Dermatol. 2008;47(2):192-194.[PubMed 18211497]

Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110-119.[PubMed 27063728]

Keystone EC, Kavanaugh AF, Sharp JYT, et al, “Radiographic, Clinical, and Functional Outcomes of Treatment With Adalimumab (A Human Anti-Tumor Necrosis Factor Monoclonal Antibody) in Patients With Active Rheumatoid Arthritis Receiving Concomitant Methotrexate Therapy: A Randomized, Placebo-Controlled, 52-Week Trial,” Arthritis Rheum, 2004, 50(5):1400-11.[PubMed 15146409]

Kingsbury DJ, Bader-Meunier B, Patel G, et al. Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years. Clin Rheumatol. 2014;33(10):1433–1441.[PubMed 24487484]

Labetoulle R, Roblin X, Paul S. Prolonged persistence of adalimumab transferred from mother to infant during pregnancy. Ann Intern Med. 2018;169(1):60-61.[PubMed 29507939]

Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol. 2018;113(4):481-517. doi: 10.1038/ajg.2018.27.[PubMed 16618399]

Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, “Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,” JAMA, 2012, 308(9): 898-908.[PubMed 22948700]

Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810-820.[PubMed 18716298]

Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43(3):172.[PubMed 10985636]

Mahadevan U, Martin CF, Sandler RS et al. PIANO: A 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142 (Suppl 1):S149.

Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Am J Obstet Gynecol. 2019;220(4):308-323. doi: 10.1016/j.ajog.2019.02.027.[PubMed 30948039]

Mahadevan U, Wolf DC, Dubinsky M, et al, "Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease,"Clin Gastroenterol Hepatol, 2013, 11(3):286-92.[PubMed 23200982]

Matro R, Martin CF, Wolf D, Shah SA, Mahadevan U. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology. 2018;155(3):696-704.[PubMed 29857090]

Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.[PubMed 30772098]

Nguyen GC, Loftus EV Jr, Hirano I, et al; AGA Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the management of Crohn's disease after surgical resection. Gastroenterology. 2017;152(1):271-275. doi: 10.1053/j.gastro.2016.10.038.[PubMed 27840074]

Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):e32-e69.[PubMed 27400984]

Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.[PubMed 22235228]

Parakkal D, Sifuentes H, Semer R, et al, “Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-α Inhibitor Therapy: Expanding the Groups at Risk,” Eur J Gastroenterol Hepatol, 2011, 23(12):1150-6.[PubMed 21941193]

Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328-344.[PubMed 19626656]

Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol. 2018;59(2):86-100.[PubMed 28543445]

Sandborn WJ, Rutgeerts P, Enns R, et al, "Adalimumab Induction Therapy for Crohn Disease Previously Treated With Infliximab: A Randomized Trial.," Ann Intern Med, 2007, 146(12):829-38.[PubMed 17470824]

Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol. 2013;108(11):1731-1742. doi: 10.1038/ajg.2013.287.[PubMed 24019080]

Seow CH, Leung Y, Vande Casteele N, et al. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(10):1329-1338.[PubMed 28318043]

Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.[PubMed 7746084]

Simonini G, Taddio A, Cattalini M, et al, "Prevention of Flare Recurrences in Childhood-Refractory Chronic Uveitis: An Open-Label Comparative Study of Adalimumab Versus Infliximab," Arthritis Care Res (Hoboken), 2011, 63(4):612-8.[PubMed 21452272]

Singh JA, Furst DE, Bharat A, et al, “2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,” Arthritis Care Res (Hoboken), 2012, 64(5):625-39.[PubMed 22473917]

Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015;148(1):64-76.e2. doi: 10.1053/j.gastro.2014.09.031.[PubMed 25263803]

Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2013;145(6):1459-1463.[PubMed 24267474]

Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55(3):340-361.[PubMed 22773060 ]

van der Heijde D, Kivitz A, Schiff MH, et al, “Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial,” Arthritis Rheum, 2006, 54(7):2136-46.[PubMed 16802350]

Weizman AV, Nguyen GC, Seow CH, et al. Appropriateness of biologics in the management of crohn's disease using RAND/UCLA appropriateness methodology. Inflamm Bowel Dis. 2019;25(2):328-335. doi: 10.1093/ibd/izy333.[PubMed 30346529]

Zelinkova Z, van der Ent C, Bruin KF, et al, "Effects of Discontinuing Anti-Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal Exposure," Clin Gastroenterol Hepatol, 2013, 11(3):318-21.[PubMed 23103819]

Brand Names: International

Amgevita (AT, BE, NL); Cyltezo (AT, BE, HR, HU, LV, NL, PT); Hadlima (AU); Halimatoz (NL); Humira (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IQ, IR, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, SY, TR, TW, UA, UY, VE, VN, YE, ZA); Hyrimoz (AT, AU, CZ, DE, EE, ES, HR, HU, LT, LV, NL, PL, PT, RO, SK); Imraldi (BE, NL); Solymbic (AT); Trudexa (BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, IT, NO, PT, RU, SE, SK, TR)

Last Updated 4/30/20